Bioxcel Therapeutics Inc (BTAI) has released an update.
BioXcel Therapeutics, Inc. recently amended its credit agreement, allowing more financial flexibility by waiving a potential default triggered by a “going concern” auditor’s opinion for the fiscal year 2023. This amendment, effective upon the company securing a minimum of $40 million through a public stock offering, demonstrates the lender’s continued support. Additionally, the company has received FDA Fast Track designation for BXCL701, a promising cancer treatment, highlighting a potential boost to BioXcel’s market position and investor interest.
For further insights into BTAI stock, check out TipRanks’ Stock Analysis page.
